Skip to main content
Premium Trial:

Request an Annual Quote

IVitalize Acquires Genetic Testing Laboratory Geneus Health

NEW YORK – Biotechnology firm iVitalize said on Tuesday that it has acquired genetic testing laboratory Geneus Health for an undisclosed amount.

San Antonio-based Geneus offers genetic testing for therapy and management of addiction and will add to iVitalize's roster of companies in this area, including the Blum Institute, MyGenx, and Cleantrac, the firm said in a statement.

Specifically, Geneus has developed and patented the Genetic Addiction Risk Score test, which identifies potential genetic predisposition to reward deficiency syndrome, a primary marker for addiction. It provides an opportunity to target treatment, particularly for patients that haven't benefited from therapy management, San Antonio-based iVitalize said.

"From genetic testing that enables targeted addiction treatment to the treatment options themselves, Geneus provides groundbreaking solutions in addiction management," Justin Jones, iVitalize's president, said in a statement.

Geneus has several CLIA- and College of American Pathologists-accredited laboratories that perform high-complexity molecular testing and offer infectious disease testing, SNP genotyping, and full-service blood testing.

It also partners with companies to provide clinical trial services, including assay development, trial site training, investigator support, and customized reporting.